tbuckley/cabot-search huggingface dataset:
473P Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
Authors: K.S. Vega Cano, G. Villacampa Javierre, P. Mascaró Baselga, O. Mirallas, E. Zamora Adelantado, L. Sanz Gomez, C. Ortiz, M. Cruellas Lapena, M. Arumi de Dios, M. Borrell Puy, F. Filippi-Arriaga, L. Joval, J.G. Yaringaño, P. Martínez-Albaladejo, P.B. Buch, P. Esteban, L. Ruiz-Ortega, C. Saura Manich, M. Riveiro-Barciela, M. Bellet Ezquerra
Journal: Annals of Oncology (2023)
2134P Self-reported late effects, need for information and follow-up in long-term Hodgkin lymphoma survivors
Authors: L.H. Willumsen, K.B. Smeland, S.A. Eikeland, A. Fossa, H. Bersvendsen, U-M. Fagerli, R.S. Falk, H.C. Lie, C.E. Kiserud
Journal: Annals of Oncology (2023)
407P Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
Authors: J.C. Radosa, T. Fietz, J. Wilke, T. Decker, V. Petersen, M. Deryal, J. Knoblich, C. Losem, U. Rhein, B. Schöttker, D. Wrobel, G. Pfeiler, E. Zanucco, J. Buncke, S. Woerner, K. Gratzke, A. Adams, E. Glastetter, R. Bartsch, M.P. Lux
Journal: Annals of Oncology (2023)
836P EX103, a re-designed CD20xCD3 bispecific antibody, showed a favorable safety and potent single-agent antitumor activity in heavily pretreated relapsed/refractory patients with B cell non-Hodgkin lymphoma
Authors: M. Sun, K. Zhou, C. Ji, F. Lu, C. Chang, W. Zhang, D. Yang, J. Lu, J. Li, Y. Cheng, Y. Li, J. Qi
Journal: Annals of Oncology (2023)
475P Dynamics of TROP2 expression in triple-negative breast cancer
Authors: A.C. Garrido-Castro, J. Gomez Tejeda Zanudo, J. Navarro, A.M. Barkell, A. Frangieh, A. Mohammed-Abreu, M.E. Hughes, B. Binboga Kurt, R.J. Hill, T.A. King, E.A. Mittendorf, M.C. Rebelatto, D. Carroll, N.U. Lin, S.M. Tolaney, E.C. De Bruin
Journal: Annals of Oncology (2023)
467P Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
Authors: I. Ceballos Lenza, E. Llabres Valenti, M. Garcia Alonso, R. Álvarez Ambite, M. Hernandez Sosa, R.E. Amurrio Quevedo, A. Rodriguez Capote, S. Hernández Sarmiento, E. Vicente Rubio, C.S. Gonzalez RIvas, M. Gutierrez Gordo, A. Mendez Perez, D. Perez Cabrera, C.V. Del Pino Hernandez, J.A.R. Rodriguez Garcia, M.A. Cabrera Suárez, S. Coca Membribes, A.M. Vargas Prado, A. Ramchandani Vaswani, J. Cruz Jurado
Journal: Annals of Oncology (2023)
822O Activation of γ9δ2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed/refractory hematologic cancers (EVICTION trial)
Authors: S. Garciaz, S. Champiat, P. Peterlin, K. Lemmens, A. de Gassart, P. Brune, E. Valentin, C. Leparquier, M. Iche, D. Olive, N. Vey, P.A. Frohna
Journal: Annals of Oncology (2023)
2133P Sleep disorders: Evolution in time in early breast cancer (EBC)
Authors: B. Cantos, J.C. Sanchez Gonzalez, M. Mendez Garcia, B. Nunez Garcia, M. Blanco Clemente, C. Parejo, M. Campos, B. Rodriguez Morilla, P.F. Almaida Pagan, S.C. González González, C. Traseira Puchol, M. Martinez Cutillas, R. Aguado, Y. Garitaonaindía Díaz, A. González Sánchez, D.I. Ruiz de Domingo, M.M. Sánchez del Corral, I. Redondo, M. Torrente, M. Provencio Pulla
Journal: Annals of Oncology (2023)
385MO A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors
Authors: J. Zhang, X. Hu, Y. Du, Y. Meng, Y. Liu, Y. Shi, J. Wang, A. Zang, S. Gu, T. Liu, H. Zhou, H. Guo, S. Xiang, X. Zhang, S. Wu, M. Li
Journal: Annals of Oncology (2023)
426P The overall survival data of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase II trial
Authors: Z. Wang, L. Chen, L. Fan, Z. Shao
Journal: Annals of Oncology (2023)
468P Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study
Authors: E. Caliskan Yildirim, E. Atag, E. Yuzugullu, O.U. Unal, A. Celebi, M. Keser, M. Uzun, M. Keskinkilic, E. Tanrikulu Simsek, M. Sari, T. Yavuzsen
Journal: Annals of Oncology (2023)
1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy
Authors: N.J. Shah, M.T. Campbell, S. Mao, M.C. Ornstein, N.B. Haas, X. Gao, H. Hammers, H. Keshava-Prasad, C.J. Hoimes, A. Hussain, S. George, T.S. Gourdin, A. Nelson, H. Yan, V. Esquibel, G. McIntyre, R. Geller, M.H. Voss, B.I. Rini, K. Beckermann
Journal: Annals of Oncology (2023)
737P Vascular fingerprint tool to identify testicular cancer patients at high-risk for early cardiovascular events after cisplatin-based chemotherapy
Authors: A.T. Meuleman, E. Volders, S. Lubberts, J.M. Kerst, M. Wymenga, M.J.B. Aarts, M. Brito Goncalves, J. Lefrandt, G. Steursma, C. Meijer, J. Nuver, J.A. Gietema
Journal: Annals of Oncology (2023)
425P Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
Authors: B.I. Tavara, M.L. Garrido, L. Lopez, M. Lopez Flores, C. Castañón, S. Abella Alvarez, S. Medina Valdivieso, A. Rodriguez Sanchez, A. García Palomo-Pérez, A. López
Journal: Annals of Oncology (2023)
1892P A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Authors: R.R. McKay, W. Xie, K. Leucht, O. Jegede, D.A. Braun, M.B. Atkins, M-O. Grimm, T.K. Choueiri
Journal: Annals of Oncology (2023)
1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Authors: R.M. Saliby, T. Jammihal, C. Labaki, H. Soulati, J. Gallegos, A. Peris, D. McCurry, C. Yu, V. Shah, D. Poduval, T. El Zarif, N. El Ahmar, Y.N. Laimon, D.Y.C. Heng, S. Signoretti, E.M. Van Allen, T.K. Choueiri, S. Shukla, D.A. Braun
Journal: Annals of Oncology (2023)
376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
Authors: S. Modi, W. Jacot, H. Iwata, Y.H. Park, M.J. Vidal Losada, W. Li, J. Tsurutani, K. Zaman, N.T. Ueno, A. Prat, K. Papazisis, H.S. Rugo, N. Harbeck, S-A. Im, M. De Laurentiis, C.M.A. Orbegoso, L. Yung, F-C. Cheng, Y. Cheng, D.A. Cameron
Journal: Annals of Oncology (2023)
835P A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Authors: K. Miyashita, W. Utsunomiya, K. Hirata, M. Higuchi, Y. Tachikawa, I. Choi, Y. Suehiro
Journal: Annals of Oncology (2023)
2140P Short-term quality-of-life after metastases-directed SBRT: Results of the prospective ESTRO &amp; EORTC OligoCare cohort
Authors: D. Greto, M. Van Hemelrijck, F. Oppong, Y. Lievens, I. Ratosa, B. Jereczek-Fossa, K. Stellamans, H. Peulen, L. Verbeke, H. Hemmatazad, S. Ramella, P. Braam, G.B. Ivaldi, P. Castro, A. Shaukat, P. Tsoutsou, S.C. Olalla, G. Sancho-Pardo, P. Ost, M. Guckenberger
Journal: Annals of Oncology (2023)
1906P Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Authors: A. Hartmann, L. Vorfelder, M. Ahrens, J.B.A.G. Haanen, B. Escudier, A. Ravaud, E. Boleti, G. Gravis, A. Flechon, M-O. Grimm, J. Bedke, B. Mellado Gonzalez, P. Ivanyi, I. Polifka, F. Lange, A. Agaimy, L. Bergmann, C.G. Stöhr
Journal: Annals of Oncology (2023)

In the 2022 WHO classification more than 20 entities of renal cell carcinomas (RCC) were defined. Several molecularly defined RCC were separated. There is urgent need for studies investigating well defined patients with these specific entities. One prerequisite is an exact classification of non-clear cell RCC (nccRCC) including histopathological and molecular diagnostics. The SUNNIFORECAST study (NCT03075423) is a phase 2 randomised investigator-initiated trial of nivolumab with ipilimumab vs. standard of care in patients with previously untreated and advanced nccRCC. For study inclusion a reference pathology to confirm diagnosis of nccRCC was mandatory. 350 cases were submitted for reference pathology as paraffin blocks or unstained slides. Diagnoses was done by HE staining, immunohistochemistry and molecular testing. Reference pathology confirmed the diagnoses of nccRCC in 334 of 350 cases. Only few cases were diagnosed in reevaluation as ccRCC, liposarcoma or epithelioid angiomyolipoma. Histopathological diagnoses included papillary RCC (n=138-41%), chromophobe RCC (n=58-17%), RCC, NOS, mostly with sarcomatoid pattern (n=46-14%) TFE3 or TFEB altered RCC (n=25 and n=1,8%), FH-deficient RCC (n=33-10%), SDHB-deficient RCC (n=4-1%), SMARCB1-deficient renal medullary carcinoma (n=9-3%), collecting duct carcinoma (n=14-4%) and tubulocystic RCC (n=1). Interestingly no tumors out of the group of other oncocytic tumous or clear cell papillary renal cell tumors were detected. Compared to primary pathology diagnosis changed in 116/350 cases. There was no correct primary diagnosis in 28/33 cases of FH-deficient RCC, 3/4 cases of SDHB deficient RCC and 17/26 cases of translocation RCC. All chromophobe RCC showed sarcomatoid dedifferentiation or coagulative tumor necrosis. In papillary renal cell carcinoma, micropapillary and microcystic architecture was very frequently detected in G1/G2 tumors. Reference pathology is a prerequisite for clinical studies investigating ncc RCC. The diagnosis of molecular defined RCC is still problematic in daily diagnosis. The study was supported by a grant of BMS (BMS).
2382P EBANO study: Clinical characteristics, treatment patterns and survival results in patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in northern Spain
Authors: R. Fernandez-Rodriguez, N. Sagastibelza, E. Pujol Obis, N. Lainez Milagro, R. Sánchez-Escribano, M. Martinez Kareaga, J.A. Verdun Aguilar, M. Arruti Ibarbia, M. Pumares Gonzalez, T. De Portugal Fernandez del Rivero, A. Lacalle, I. Gil Arnaiz, A. Pereira-Elorrieta, I. Duran Martinez
Journal: Annals of Oncology (2023)
1200P A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial
Authors: O. Clemente, N. Starita, A. Bracigliano, M. Cives, F. Tatangelo, M.L. Barretta, G. Badalamenti, S. Lastoria, F. Picozzi, A. Di Mauro, C. von Arx, L. Cannella, S. Tafuto
Journal: Annals of Oncology (2023)
2192P Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Authors: A. Mittal, L. Everest, D. Patel, L.J. Zhan, C. Brown, F. Zaeimi, S. Schmid, K. Khan, K. Dietrich, K. Balaratnam, M. García Pardo de Santayana, L. Eng, A. Sacher, F.A. Shepherd, N. Leighl, J. Cho, M. de Perrot, G. Liu, P. Bradbury
Journal: Annals of Oncology (2023)

Real world QoL data and association with overall survival (OS) for pts with advanced mesothelioma is scarce. Moreover, the associations between health utility scores (HUS) generated from EQ-5D and symptoms as measured by ESAS and pro-CTCAE remain unknown in aMPM pts. Through retrospective chart review, clinico-demographic variables and treatment information were captured in pts diagnosed with aMPM between Jan 1, 2004, to Feb 1, 2021 at Princess Margaret Cancer Centre. QoL outcomes were measured using HUS by EQ-5D, ESAS, and pro-CTCAE scales. Changes in QoL were examined by disease state. Survival was examined by baseline QoL using the KM method. Correlation between QoL scales was examined using Spearman's r. Of 172 pts with baseline QoL data, median age was 69.6 yrs; 73% were males; 52% were ever smokers; 57% had epithelioid aMPM; 82% received systemic therapy for advanced disease. Based on a mixed effects regression model, ESAS pooled physical and pooled psychological were worst at baseline, improved at stable /responding disease (physical, p=0.001; psychological, p=0.001) and worsened at progressive disease (physical, p=0.003; psychological, p=0.02). Similar trends were seen in HUS (stable to progressive disease p=0.03), and pro-CTCAE symptom severity (baseline to stable disease p=0.03) and frequency (baseline to stable disease p=0.008). Pts with high baseline ESAS physical burden had inferior OS: median 12.1 (high) vs 8.2 months (low) p=0.023, with no impact of psychological burden on OS. Weak to moderate correlations were observed between ESAS domains and HU as well as pro-CTCAE domains and HU. Strongest domain correlations were well-being (ESAS r=-0.39), tiredness/ fatigue (ESAS r=-0.39, severity r=-0.38, interference r=-0.44), and shortness of breath (severity r=-0.35, interference r=-0.44), each p<0.05. Both HUS and ESAS captured disease state well. Individual ESAS and pro-CTCAE domains showed moderate correlations with HUS, thus validating such scores for future integration into routine clinical care. Physical symptom burden as captured by ESAS impacted OS and could be used as a prognostic tool, if validated in prospective studies.
458P Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey
Authors: C. Lisanti, A. Costantini, B. Pastò, M. Garutti, S. Bolzonello, L. Da Ros, P. Di Nardo, S. Corsetti, L. Gerratana, S. Scalone, S. Spazzapan, M.S. Nicoloso, S. Della Rossa, M. Rizzetto, A. Membrino, S. Cinieri, A. Bonifacino, F. Puglisi
Journal: Annals of Oncology (2023)
421P Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Authors: T. Iwamoto, K-I. Watanabe, N. Niikura, T. Takeshita, Y. Kikawa, K. Kobayashi, N. Iwakuma, T. Okamura, H. Tada, S. Ozaki, T. Okuno, U. Toh, Y. Yamamoto, M. Tsuneizumi, H. Ishiguro, N. Masuda, S. Saji
Journal: Annals of Oncology (2023)
1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)
Authors: E. Verzoni, G. Procopio, A. Bottiglieri, M. Stellato, A. Rametta, P.A. Zucali, B. Perrucci, None G. fornarini, S. Buti, M. Maruzzo, A. Cova, P. Squarcina, L. Lalli, A. Mereu, N. Cerioli, L. Agnelli, K. Todoerti, A. Busico, L. Rivoltini, V. Huber
Journal: Annals of Oncology (2023)
2398P Are fibroblast growth factor receptor 3 (FGFR3) alterations a possible predictive factor for platinum-based chemotherapy and immunotherapy in metastatic urothelial carcinoma (MUC)?
Authors: L. Ferrer-Mileo, A. Rodriguez Hernandez, C. Aversa, L. Rodríguez-Carunchio, I. Ribera, I. Trias Puigsureda, L. Oliva, N. Jimenez Blasco, S. García-Esteve, M. Álvarez, M. Rabella, B. Mellado Gonzalez, O. Reig Torras
Journal: Annals of Oncology (2023)
1197P Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
Authors: M.G. Maratta, S. Chiloiro, S. Raia, B.A. Maiorano, G. Horn, M.G. Brizi, V. Rufini, L. De Marinis, A. Bianchi, G. Schinzari, F. Inzani, G. Tortora, G. Rindi
Journal: Annals of Oncology (2023)
1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Authors: C. Gedye, C.A. Harris, M.R. Stockler, M. Morris, T. Ferguson, J.C.H. Goh, A. Martin, C.R. Underhill, D. Pook, L.E.M. Krieger, G. Kichenadasse, A.J. Joshi, S. Subramaniam, D.S. Zebic, A. Zhang, A.M. Joshua, G.C. Toner, P.A. Vasey, P. Prithviraj, I.D. Davis
Journal: Annals of Oncology (2023)
2171P Incidence of adverse events in patients treated with a combination of immune checkpoint blockers and chemotherapy: A real life cohort
Authors: L.W. Rached, A. Laparra, M. Aldea, F-X. Danlos, O. Lambotte, A. Marabelle, B. Besse, D. Planchard, A. Perret, M. Sakkal, S. Messayke, F. Scotté, S. Champiat, A. Hollebecque, C. Even, C. Smolenschi, J.T.M.L. Ribeiro, B. Pistilli, S. Ponce Aix, C. Baldini
Journal: Annals of Oncology (2023)
2135P Impact of geriatric assessment (GA) and geriatric 8(G8)-based targeted interventions on the quality of life (QoL) in older Asian adults with cancer
Authors: J.L. Low, J. Cheng, A. Ng, M. Chun, Y.S. Lim, C.E. Chee, J. Tey, F. Ho, M.Z. Chen, S.L.A. Pang, N.K. Barr
Journal: Annals of Oncology (2023)
2202P Large cell neuroendocrine carcinoma (LCNEC) subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression
Authors: F. Heijboer, J. Derks, N. Rijnsburger, B. Hermans, L. Hillen, E. van den Broek, E-J. Speel, A-M.C. Dingemans, J. von der Thüsen
Journal: Annals of Oncology (2023)
1975P Systemic therapy for KIT/PDGFRA wild-type GIST
Authors: M. Brahmi, A. Dufresne, A. Pattee, H. Vanacker, A. Meurgey, D. Pissaloux, P. Meeus, M-P. Sunyach, M. Karanian, A. Bouhamama, F. Tirode, P. Cassier, I.L. Ray-Coquard, J-Y. Blay
Journal: Annals of Oncology (2023)
1609P A machine learning-based prognostic model to predict survival in patients with advanced cancer admitted to an acute palliative care unit
Authors: E.H. Jung, Y. Park, Y.J. Kim, S. Yi, K. Kim, J. Oh, S. Lee, B. Kang, K.J. Suh, J.Y. Lee, J-W. Kim, S.H. Kim, J.W. Kim, J-O. Lee, K-W. Lee, J.H. Kim, S-M. Bang, J-S. Lee
Journal: Annals of Oncology (2023)
1191P TTF-1 expression in lung neuroendocrine tumors (NET): A gender-related biomarker
Authors: A. La Salvia, A. Siciliani, M. Rinzivillo, M. Verrico, R. Baldelli, G. Puliani, R. Modica, I. Zanata, I. Persano, G. Fanciulli, M. Bassi, M. Mancini, E. Giannetta, S. Bellino, M. Ibrahim, F. Panzuto, M.P. Brizzi, A. Faggiano
Journal: Annals of Oncology (2023)
1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study
Authors: N. Agarwal, J. Brugarolas, P. Ghatalia, S. George, J.B.A.G. Haanen, H.P. Gurney, R. Ravilla, A.A.M. Van der Veldt, B. Beuselinck, I. Pokataev, B.B. Suelmann, M. Tuthill, D. Vaena, F. Zagouri, J. Wu, Y. Liu, R. Perini, J.R. Merchan, M.B. Atkins
Journal: Annals of Oncology (2023)
1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC
Authors: V. Navani, A. Lemelin, T.B. Powles, E.C.H. Liow, S.S.L. Wong, L.A. Meza, H. Ebrahimi, R.M. Saliby, E. Saad, T. Yuasa, L.A. Wood, C.K. Kollmannsberger, J. Graham, S. North, N.S. Basappa, F. Donskov, C. Suarez Rodriguez, A-K. Lalani, T.K. Choueiri, D.Y.C. Heng
Journal: Annals of Oncology (2023)
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study
Authors: Karen A. Veverka, Steven T.G. Thng, Jonathan I. Silverberg, April W. Armstrong, Josemund Menezes, Alexandre Kaoukhov, Andrew Blauvelt
Journal: Journal of the American Academy of Dermatology (2023)

Eblasakimab, an interleukin (IL)-13 receptor α1 antagonist, blocks IL-4 and IL-13 signaling through the type 2 receptor.
439P Testing HR+ / HER2- patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)
Authors: A. Boutis, M. Nikolaou, A. Ardavanis, C. Tolis, K. Loga, I. Korantzis, A. Koumarianou, A.N. Christopoulou, G. Papatsimpas, A. Bokas, K. Pliarchopoulou, E. Kampletsas, G. Kesisis, E. Biziota, K. Psianou, S. Karageorgopoulou, E.A. Sogka, N.G. Tsoukalas, N. Chatzifoti, Z. Saridaki-Zoras
Journal: Annals of Oncology (2023)
1885P Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTI-PD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II study
Authors: S.Y. Rha, W.K. Bae, C. Kim, S.Y. Oh, H.W. Lee, K. Park, N. Mar, G. Kichenadasse, H.K. Ha, R. Pachynski, I. Park, K.H. Park, S.H. Kim, E. Folefac, M.D. Mathias, F. Seebach, S. Ma, L. Carranza, S-H. Beom, J.R. Merchan
Journal: Annals of Oncology (2023)
2156P Use of taxanes during pregnancy: A systematic review
Authors: A.S. Ferrigno Guajardo, B.F. Vaca Cartagena, A. Aranda Gutierrez, A. Becerril Gaitan, H. Azim, C.M. Villarreal Garza
Journal: Annals of Oncology (2023)

The use of chemotherapy (CT) with taxanes after the first trimester of pregnancy is endorsed by guidelines despite limited data on their safety. This study aims to review the neonatal and obstetric outcomes after the use of taxanes during pregnancy. A MEDLINE search was performed up to 1/1/2023. Inclusion criteria included gestational taxane use, original findings, and reporting of individual patient outcomes. A total of 69 out of 316 references identified were included. Overall, 143 cases of gestational taxane use have been reported in the literature, resulting in 145 fetuses exposed in utero. Most received paclitaxel (78%) and were diagnosed with breast (59%), cervix (23%), or ovarian (13%) malignancies. Taxanes were initiated most frequently in the 2nd (69%) or 3rd trimesters (28%) of pregnancy (n=110), at a median gestational age of 17 weeks (range 2-32; n=89). The median cumulative dose received during pregnancy was 405 mg/m2 (range: 125-1200; n=63) for paclitaxel and 320 mg/m2 (range: 160-650; n=12) for docetaxel. Out of 107 cases, 91% received other CT agents during pregnancy, including platinums (50.4%) or doxorubicin/cyclophosphamide (17.8%). No maternal adverse events or obstetric complications were reported in 54% (41/97). The most frequent adverse obstetric events were preterm contractions (12/121; 10%), pre-eclampsia (6/97; 6%), intrauterine growth restriction (7/97; 7%), oligohydramnios (5/97; 5%), and preterm premature rupture of membranes (6/120; 5%). All cases with data available resulted in live birth (n=117). Preterm birth was reported in 63% (82/131) and 29% of neonates were classified as small for gestational age (36/123). Perinatal complications were documented in 18% (20/109), including one case of neonatal death secondary to multiple congenital malformations that had been detected before CT start. A congenital malformation was reported in 4% (6/142). Information of health status after birth was available for 85 cases (median follow-up 19 months, range 1 to 160), of which 87% were reported as healthy. Two cases of pediatric malignancy were noted. Data on gestational taxane use is largely limited to case reports and small case series with heterogeneous reporting of outcomes. Future studies are urgently needed to evaluate their safety.
2190P First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Authors: G.E. Evangelou, I. Vamvakaris, V. Kolintzikis, V. Nikolaidou, O. Fiste, V. Koliaraki, E.A. Kotteas, K. Syrigos
Journal: Annals of Oncology (2023)
2157P A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1
Authors: S. Clive, A. Bularga, P. Henriksen, D.E. Newby, L.R. Wall, L. Dawson, E.R. Brown, E. Evans, S. Denham, N. Homer, O. Demyanov, S. Muir, G. Tapia-Rico, N. Peel, A. Christie
Journal: Annals of Oncology (2023)
2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Authors: L.J. Wirth, V. Subbiah, F.P. Worden, B.J. Solomon, B. Robinson, J. Hadoux, P. Tomasini, D. Weiler, B. Deschler-Baier, D.S.W. Tan, Y. Lin, T. Bayt, P. Maeda, A. Drilon, P. Cassier
Journal: Annals of Oncology (2023)
2403P CDKN2A deletions are a mechanism for p16 inactivation in urothelial bladder carcinomas and are associated with an aggressive tumor phenotype
Authors: M. Kluth, V. Ahlburg, E. Bady, K. Kornienko, H. Plage, M. Lennartz, N.C. Blessin, A.H. Marx, M. Fisch, M. Slojewski, D.M.K. Kaczmarek, P.D.T. Ecke, S. Koch, S. Minner, R. Simon, G. Sauter, T. Klatte, T. Schlomm, D. Horst, H. Zecha
Journal: Annals of Oncology (2023)